Jazz Pharma: FDA Panel Live Blog - TheStreet

Jazz Pharma: FDA Panel Live Blog

Here's our live coverage of the FDA review of Jazz's fibromyalgia drug JZP-6.
Publish date:

PALO ALTO, Calif. (


) --

Jazz Pharmaceuticals

(JAZZ) - Get Report

brings its drug JZP-6 in front of an advisory committee of the U.S. Food and Drug Administration today, seeking a positive recommendation as a treatment for fibromyalgia.

Follow all the action from today's FDA advisory panel on our live blog.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on



Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.